Aytu BioPharma, Inc. (AYTU)
NASDAQ: AYTU · Real-Time Price · USD
2.190
+0.290 (15.26%)
At close: Oct 6, 2025, 4:00 PM EDT
2.240
+0.050 (2.28%)
Pre-market: Oct 7, 2025, 4:01 AM EDT
Aytu BioPharma Stock Forecast
Stock Price Forecast
The 3 analysts that cover Aytu BioPharma stock have a consensus rating of "Strong Buy" and an average price target of $9.17, which forecasts a 318.72% increase in the stock price over the next year. The lowest target is $7.00 and the highest is $12.5.
Price Target: $9.17 (+318.72%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aytu BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 1 | 2 | 2 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 1 | 2 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy Maintains $9 → $7 | Strong Buy | Maintains | $9 → $7 | +219.63% | Sep 25, 2025 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $12 → $13 | Strong Buy | Maintains | $12 → $13 | +470.78% | Sep 25, 2025 |
| Lake Street | Lake Street | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +265.30% | Jul 1, 2025 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +447.95% | Jun 30, 2025 |
| Maxim Group | Maxim Group | Strong Buy Initiates $5 | Strong Buy | Initiates | $5 | +128.31% | Aug 9, 2023 |
Financial Forecast
Revenue This Year
63.56M
from 66.38M
Decreased by -4.26%
Revenue Next Year
75.65M
from 63.56M
Increased by 19.03%
EPS This Year
-0.87
from -2.16
EPS Next Year
0.67
from -0.87
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 75.6M | 77.9M | |
| Avg | 63.6M | 75.7M | |
| Low | 51.3M | 72.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 13.9% | 22.5% | |
| Avg | -4.3% | 19.0% | |
| Low | -22.7% | 14.4% |
EPS Forecast
| EPS | 2026 | 2027 |
|---|---|---|
| High | 0.09 | 0.69 |
| Avg | -0.87 | 0.67 |
| Low | -1.85 | 0.65 |
EPS Growth
| EPS Growth | 2026 | 2027 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.